Hikma Pharmaceuticals has announced that it will buy back approximately £295m ($367m) worth of shares from Boehringer Ingelheim, representing the firm’s full holding in Hikma.
Hikma Set To Buy Back £295m In Shares
Firm Welcomes New Investors As It Buys Back Boehringer Ingelheim Shares
Boehringer Ingelheim, which holds a 16.4% share of Hikma along with voting rights, is ready to exit the company altogether as Hikma decides to buy back £295m worth of shares. Hikma has invited new investors, expressing confidence in its future plans.
More from Deals
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.
• By
After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.
• By
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
More from Business
• By
Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.
• By
With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.
• By
Denosumab competition is heating up in Europe, with four more companies this month gaining EMA endorsements for their Prolia and Xgeva biosimilar rivals.